Determination of the MEC90 of Oxycodone for Preventing Perioperative Shivering in Pregnant Patients Undergoing Caesarean Delivery with Neuraxial Anaesthesia: A Biased-Coin up-and-Down Sequential Allocation Trial.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-02-11 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S497239

Xinlei Lu, Kaiyu Chen, Ye Xuan, Mengting Shen, Weiping Lei, Yaqin Huang, Jianliang Sun

{"title":"Determination of the MEC90 of Oxycodone for Preventing Perioperative Shivering in Pregnant Patients Undergoing Caesarean Delivery with Neuraxial Anaesthesia: A Biased-Coin up-and-Down Sequential Allocation Trial.","authors":"Xinlei Lu, Kaiyu Chen, Ye Xuan, Mengting Shen, Weiping Lei, Yaqin Huang, Jianliang Sun","doi":"10.2147/DDDT.S497239","DOIUrl":null,"url":null,"abstract":"Background: Perioperative shivering is a common adverse reaction to neuraxial anaesthesia. Intravenous oxycodone can be used to prevent shivering. However, few trials have been conducted on the use of oxycodone to prevent shivering, and the optimal dose is unknown. This study aimed to determine the optimal dose (90% minimum effective concentration [MEC90]) of intraoperative oxycodone to prevent shivering during caesarean section.Methods: This study was designed by the biased-coin up-and-down method. We recruited pregnant women who underwent caesarean section under combined spinal-epidural anaesthesia. Oxycodone was administered intravenously after the delivery of the foetus. The initial dose was 80 µg/kg, and subsequent dose adjustments were determined by up-and-down sequential allocation using a biased-coin design based on the response of the previous patient. The primary outcome was the MEC90 for oxycodone injection based on the success or failure of the shivering-preventing dose.Results: Fifty patients were enrolled in the study. The oxycodone dose ranged from 80 to 95 µg/kg. The estimated MEC90 (95% confidence interval [CI]) for preventing shivering was 88.1 µg/kg (81.5-92.5 µg/kg). The patient's postoperative temperature was 36.5 ± 0.2 °C. The incidence of intraoperative traction pain was 12%. The 5-min and 30-min Ramsay sedation scores were 3 (3-4) and 3 (3-3), respectively. The 2-h and 6-h postoperative VAS scores were 3 (2-3) and 4 (3-5), respectively. The patient's anaesthesia satisfaction score was 5 (4-5). The incidence of respiratory depression was 2%, and the incidence of nausea and vomiting was 16%.Conclusion: The MEC90 of intraoperative intravenous oxycodone for the prevention of shivering in women undergoing caesarean section with neuraxial anaesthesia was 88.1 µg/kg (95% CI: 81.5-92.5 µg/kg).","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"945-954"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829597/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S497239","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Perioperative shivering is a common adverse reaction to neuraxial anaesthesia. Intravenous oxycodone can be used to prevent shivering. However, few trials have been conducted on the use of oxycodone to prevent shivering, and the optimal dose is unknown. This study aimed to determine the optimal dose (90% minimum effective concentration [MEC90]) of intraoperative oxycodone to prevent shivering during caesarean section.

Methods: This study was designed by the biased-coin up-and-down method. We recruited pregnant women who underwent caesarean section under combined spinal-epidural anaesthesia. Oxycodone was administered intravenously after the delivery of the foetus. The initial dose was 80 µg/kg, and subsequent dose adjustments were determined by up-and-down sequential allocation using a biased-coin design based on the response of the previous patient. The primary outcome was the MEC90 for oxycodone injection based on the success or failure of the shivering-preventing dose.

Results: Fifty patients were enrolled in the study. The oxycodone dose ranged from 80 to 95 µg/kg. The estimated MEC90 (95% confidence interval [CI]) for preventing shivering was 88.1 µg/kg (81.5-92.5 µg/kg). The patient's postoperative temperature was 36.5 ± 0.2 °C. The incidence of intraoperative traction pain was 12%. The 5-min and 30-min Ramsay sedation scores were 3 (3-4) and 3 (3-3), respectively. The 2-h and 6-h postoperative VAS scores were 3 (2-3) and 4 (3-5), respectively. The patient's anaesthesia satisfaction score was 5 (4-5). The incidence of respiratory depression was 2%, and the incidence of nausea and vomiting was 16%.

Conclusion: The MEC90 of intraoperative intravenous oxycodone for the prevention of shivering in women undergoing caesarean section with neuraxial anaesthesia was 88.1 µg/kg (95% CI: 81.5-92.5 µg/kg).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.